Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy.

Fredman G, Tabas I.

Am J Pathol. 2017 Jun;187(6):1211-1221. doi: 10.1016/j.ajpath.2017.01.018. Review.

PMID:
28527709
2.

DBA/2J Haplotype on Distal Chromosome 2 Reduces Mertk Expression, Restricts Efferocytosis, and Increases Susceptibility to Atherosclerosis.

Kayashima Y, Makhanova N, Maeda N.

Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):e82-e91. doi: 10.1161/ATVBAHA.117.309522. Epub 2017 May 4.

PMID:
28473436
3.
4.

The Role of Efferocytosis in Atherosclerosis.

Kojima Y, Weissman IL, Leeper NJ.

Circulation. 2017 Jan 31;135(5):476-489. doi: 10.1161/CIRCULATIONAHA.116.025684.

PMID:
28137963
5.

MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis.

Cai B, Thorp EB, Doran AC, Sansbury BE, Daemen MJ, Dorweiler B, Spite M, Fredman G, Tabas I.

J Clin Invest. 2017 Feb 1;127(2):564-568. doi: 10.1172/JCI90520. Epub 2017 Jan 9.

6.

Rab17 mediates differential antigen sorting following efferocytosis and phagocytosis.

Yin C, Kim Y, Argintaru D, Heit B.

Cell Death Dis. 2016 Dec 22;7(12):e2529. doi: 10.1038/cddis.2016.431.

7.

2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular-Cellular Mechanisms in the Progression of Atherosclerosis.

Tabas I.

Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):183-189. doi: 10.1161/ATVBAHA.116.308036. Epub 2016 Dec 15.

PMID:
27979856
8.

Deficiency of AXL in Bone Marrow-Derived Cells Does Not Affect Advanced Atherosclerotic Lesion Progression.

Subramanian M, Proto JD, Matsushima GK, Tabas I.

Sci Rep. 2016 Dec 13;6:39111. doi: 10.1038/srep39111.

9.

Complement Protein C1q Enhances Macrophage Foam Cell Survival and Efferocytosis.

Pulanco MC, Cosman J, Ho MM, Huynh J, Fing K, Turcu J, Fraser DA.

J Immunol. 2017 Jan 1;198(1):472-480. Epub 2016 Nov 28.

PMID:
27895181
10.

Mineralocorticoid Receptor Deficiency in Macrophages Inhibits Atherosclerosis by Affecting Foam Cell Formation and Efferocytosis.

Shen ZX, Chen XQ, Sun XN, Sun JY, Zhang WC, Zheng XJ, Zhang YY, Shi HJ, Zhang JW, Li C, Wang J, Liu X, Duan SZ.

J Biol Chem. 2017 Jan 20;292(3):925-935. doi: 10.1074/jbc.M116.739243. Epub 2016 Nov 23.

PMID:
27881672
11.

Macrophage Apoptosis and Efferocytosis in the Pathogenesis of Atherosclerosis.

Linton MF, Babaev VR, Huang J, Linton EF, Tao H, Yancey PG.

Circ J. 2016 Oct 25;80(11):2259-2268. Epub 2016 Oct 8. Review.

12.

An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.

Fredman G, Hellmann J, Proto JD, Kuriakose G, Colas RA, Dorweiler B, Connolly ES, Solomon R, Jones DM, Heyer EJ, Spite M, Tabas I.

Nat Commun. 2016 Sep 23;7:12859. doi: 10.1038/ncomms12859.

13.

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes.

Wasiak S, Gilham D, Tsujikawa LM, Halliday C, Norek K, Patel RG, McLure KG, Young PR, Gordon A, Kulikowski E, Johansson J, Sweeney M, Wong NC.

Data Brief. 2016 Jul 29;8:1280-8. doi: 10.1016/j.dib.2016.07.047. eCollection 2016 Sep.

14.

CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.

Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusis AJ, Miller CL, Direnzo D, Nanda V, Ye J, Connolly AJ, Schadt EE, Quertermous T, Betancur P, Maegdefessel L, Matic LP, Hedin U, Weissman IL, Leeper NJ.

Nature. 2016 Aug 4;536(7614):86-90. Epub 2016 Jul 20.

15.

MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation.

Cai B, Thorp EB, Doran AC, Subramanian M, Sansbury BE, Lin CS, Spite M, Fredman G, Tabas I.

Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):6526-31. doi: 10.1073/pnas.1524292113. Epub 2016 May 19.

16.

Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis.

Kamaly N, Fredman G, Fojas JJ, Subramanian M, Choi WI, Zepeda K, Vilos C, Yu M, Gadde S, Wu J, Milton J, Carvalho Leitao R, Rosa Fernandes L, Hasan M, Gao H, Nguyen V, Harris J, Tabas I, Farokhzad OC.

ACS Nano. 2016 May 24;10(5):5280-92. doi: 10.1021/acsnano.6b01114. Epub 2016 Apr 28.

17.

The clearance of dying cells: table for two.

Green DR, Oguin TH, Martinez J.

Cell Death Differ. 2016 Jun;23(6):915-26. doi: 10.1038/cdd.2015.172. Epub 2016 Mar 18. Review.

18.

Leukocytes Link Local and Systemic Inflammation in Ischemic Cardiovascular Disease: An Expanded "Cardiovascular Continuum".

Libby P, Nahrendorf M, Swirski FK.

J Am Coll Cardiol. 2016 Mar 8;67(9):1091-103. doi: 10.1016/j.jacc.2015.12.048. Review.

19.

The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach.

Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D, Blue M, Zhang J, Bracci P, Bshara W, Behr S, Maurer T, Williams K, Walker J, Beverly A, Blay B, Damughatla A, Larsen M, Mountain C, Neylon E, Parcel K, Raghuraman K, Ricks K, Rose L, Sivakumar A, Streck N, Wang B, Wasco C, Williams A, McGrath M.

Nucl Med Biol. 2016 Mar;43(3):215-25. doi: 10.1016/j.nucmedbio.2015.11.007. Epub 2015 Dec 3. Review.

20.

Differential effects of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 on atherosclerosis and monocyte/macrophage invasion.

Di Gregoli K, George SJ, Jackson CL, Newby AC, Johnson JL.

Cardiovasc Res. 2016 Feb 1;109(2):318-30. doi: 10.1093/cvr/cvv268. Epub 2015 Dec 8.

Supplemental Content

Support Center